ASCO 2023 Highlights

Improving clinical outcomes in the second line of treatment in patients with advanced biliary tract cancer remains an important goal, and researchers have been exploring various therapeutic targets, including HER2, an oncogene that creates a protein that encourages cell growth and accelerates the spread of cancers. Read More ›

Chicago, IL—It is well documented that clinical trials thus far have for the most part excluded underserved populations, and that means the results of these trials cannot be generalized to society at large. Fortunately, the federal government and medical societies have taken aim at remedying this imbalance in accrual for clinical trials. Read More ›

Chicago, IL—The addition of the PD-1 inhibitor pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in a substantial and clinically meaningful improvement in overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the phase 3 KEYNOTE-826 trial. Read More ›

Chicago, IL—The presidential theme for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting was “Partnering With Patients: The Cornerstone of Clinical Care and Research.” In his address during the opening session of the meeting, Eric P. Winer, MD, FASCO, Director, Yale Cancer Center, and Physician-in-Chief, Smilow Cancer Hospital at Yale New Haven, CT, and ASCO’s 2022-2023 President, discussed the importance of physician–patient partnerships for improving healthcare outcomes. Read More ›

Chicago, IL—The addition of the CDK4/6 inhibitor ribociclib (Kisqali) to endocrine therapy significantly improved invasive disease-free survival in patients with hormone receptor (HR)-positive, HER2-negative, early breast cancer, according to interim results of the phase 3 NATALEE trial, which were presented at the 2023 American Society of Clinical Oncology Annual Meeting. Read More ›

Chicago, IL—Interim results from the phase 3 COMMANDS trial demonstrated that first-line treatment with luspatercept-aamt (Reblozyl) increased hemoglobin levels and enabled nearly twice as many patients with transfusion-dependent, lower-risk myelodysplastic syndromes to avoid red blood cell transfusions during the first 24 weeks of the study compared with standard-of-care epoetin alfa. Read More ›

The National Prescription Drug Take-Back addresses a vital public safety and public health issue. Many patients are not aware that the medicines in their cabinets are highly susceptible to diversion, misuse, and abuse. Read More ›

Adherence to certain strategies can aid pharmacists in successful navigation of our increasingly collaborative healthcare landscape. Read More ›